Press Release > CordenPharma Completes Acquisition of Three Manufacturing Facilities from Vifor Pharma
CordenPharma Completes Acquisition of Three Manufacturing Facilities from Vifor Pharma
1
February 2022 – Luxembourg > CordenPharma,
a leading, full-service Contract Development & Manufacturing Organization
(CDMO) supplying APIs, Excipients, Drug Products, and associated Packaging
services, announced today the completion of the acquisition of three
manufacturing facilities from Vifor Pharma, to be ultimately renamed Corden Pharma
Fribourg S.A. (including its Ettingen branch) in Switzerland, and Corden Pharma
Lisbon S.A. in Portugal.
As the next step of our strategy to provide customers with rapid and economically attractive solutions, CordenPharma is delighted to announce the addition of a second 100 cm high-pressure chromatography column at CordenPharma Colorado, to accommodate the continuous growth and evolution of the peptide therapeutic market. Matthieu Giraud, PhD, Global Director of the Peptides, Lipids & Carbohydrates Platform explains, “This additional column will provide the capacity to purify several tons of peptide annually, which in conjunction with our existing 100 and 80 cm columns, gives us more flexibility and redundancy to maximize supply security for all of our partners.”
CordenPharma’s strategy focuses on staying ahead of expanding global market needs by investing in new equipment and technologies to constantly improve the productivity of our peptide assets – in particular via the deployment of innovative Process Analytical Technology (PAT).
The new column is already installed and will be qualified by the end of Q2 2021.
Dr. Michael
Quirmbach, Chief Executive Officer & President of CordenPharma said, “We
welcome the three sites and their employees as new members to the CordenPharma
Group and look forward to working with Vifor in the future to supply Vifor
Pharma’s finished drug products, including to their already existing customers.
The acquired pharma sites have a well-trained workforce with great cultural
fit, state-of-the art infrastructure, and a strong compliance track record.
This excellent opportunity aligns well with our strategy to broaden our CDMO
capabilities.”
The
acquisition of the Vifor Pharma manufacturing sites will expand CordenPharma’s
capabilities and capacities in the manufacturing of non-sterile drug product
dosage forms, including but not limited to, Oral Solid Dosage (OSD) forms such
as tablets and capsules. With the addition of these three new facilities,
CordenPharma's global network now consists of twelve locations (11 GMP sites
and 1 R&D laboratory), supported by > 2,600 employees generating
expected sales of over 800 Mio € in 2022.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance